Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions

References

• Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review. J Clin Oncol. 2018;36(16):1631–1641. doi:10.1200/JCO.2017.76.8671
   PubMed Web of Science ®Google Scholar
• Pellini B, Szymanski J, Chin RI, Jones PA, Chaudhuri AA. Liquid biopsies using circulating tumor DNA in non-small cell lung cancer. Thorac Surg Clin. 2020;30(2):165–177.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Soo RA, Martini J-F, van der Wekken AJ, et al. Early circulating tumor (ct) DNA dynamics and efficacy of lorlatinib: analysis from the CROWN study. J Clin Oncol. 2021;39(15_suppl):9011.
   Web of Science ®Google Scholar
• Gray JE, Okamoto I, Sriuranpong V, et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res. 2019;25(22):6644–6652.
   PubMed Web of Science ®Google Scholar
• Weber S, van der Leest P, Donker HC, et al. Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. JCO Precis Oncol. 2021;5:1540–1553.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou F, Qiao M, et al. The role of circulating tumor DNA in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2021;11:671874.
   PubMedGoogle Scholar
• Lim Y, Kim S, Kang J-K, et al. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. Sci Rep. 2021;11(1):16333.
   PubMed Web of Science ®Google Scholar
• Hrebien S, Citi V, Garcia-Murillas I, et al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol. 2019;30(6):945–952.
   PubMed Web of Science ®Google Scholar
• Raja R, Kuziora M, Brohawn PZ, et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res. 2018;24(24):6212–6222. doi:10.1158/1078-0432.CCR-18-0386
   PubMed Web of Science ®Google Scholar
• Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715–1722. doi:10.1093/annonc/mdv177
   PubMed Web of Science ®Google Scholar
• Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol. 2019;30(9):1472–1478. doi:10.1093/annonc/mdz200
   PubMed Web of Science ®Google Scholar
• Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229–239.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer. J Thorac Oncol. 2021;16(10):1647–1662.
   PubMed Web of Science ®Google Scholar
• Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group. Ann Oncol. 2022;2022:1.
   Google Scholar
• Chabon JJ, Hamilton EG, Kurtz DM, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580(7802):245–251.
   PubMed Web of Science ®Google Scholar
• Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021;2021:1.
   Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451.
   PubMed Web of Science ®Google Scholar
• Natera. Signatera: seeing beyond the limit: detect residual disease and assess treatment response; 2019. Available from: https://www.natera.com/wp-content/uploads/2020/11/Oncology-Clinical-Seeing-beyond-The-limit-Detect-residual-disease-and-assess-treatment-response-SGN_AV_WP.pdf. Accessed March 13, 2023.
   Google Scholar
• RaDaR Technology overview; 2022. Available from: https://www.inivata.com/radar-technology-overview/. Accessed March 13, 2023.
   Google Scholar
• Gale D, Heider K, Ruiz-Valdepenas A, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol. 2022;33(5):500–510.
   PubMed Web of Science ®Google Scholar
• Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394–1403.
   PubMed Web of Science ®Google Scholar
• Moding EJ, Liu Y, Nabet BY, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer. Nat Cancer. 2020;1(2):176–183.
   PubMedGoogle Scholar
• Jun S, Shukla N, Durm GA, et al. Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non–small cell lung cancer. J Clin Oncol. 2022;40(16_suppl):8534.
   Web of Science ®Google Scholar
• AVENIO tumor tissue targeted kit. Available from: https://sequencing.roche.com/en/products-solutions/products/ngs-oncology-assays/tumor-tissue-analysis-kits/tumor-tissue-targeted-kits.html. Accessed March 13, 2023.
   Google Scholar
• AVENIO ctDNA expanded kit; 2022. Available from: https://sequencing.roche.com/en/products-solutions/products/ngs-oncology-assays/ctdna-analysis-kits/ctdna-expanded-kits.html. Accessed March 13, 2023.
   Google Scholar
• Roche. AVENIO ctDNA Surveillance Kit; 2018. Available from: https://sequencing.roche.com/content/dam/rochesequence/worldwide/resources/brochure-avenio-ctdna-surveillance-kit-SEQ100048.pdf. Accessed March 13, 2023.
   Google Scholar
• Kurtz DM, Soo J. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39(12):1537–1547.
   PubMed Web of Science ®Google Scholar
• Pich O, Bailey C, Watkins TBK, Zaccaria S, Jamal-Hanjani M, Swanton C. The translational challenges of precision oncology. Cancer Cell. 2022;40(5):458–478.
   PubMed Web of Science ®Google Scholar
• Zviran A, Schulman RC, Shah M, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26(7):1114–1124.
   PubMed Web of Science ®Google Scholar
• Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745–759.
   PubMed Web of Science ®Google Scholar
• Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167–1177.
   PubMed Web of Science ®Google Scholar
• Guardant. Guardant Reveal™ liquid biopsy test. Available from: https://guardanthealth.com/wp-content/uploads/Backgrounder-Guardant-Reveal-1.pdf. Accessed March 13, 2023.
   Google Scholar
• Underhill HR. Leveraging the fragment length of circulating tumour DNA to improve molecular profiling of solid tumour malignancies with next-generation sequencing: a pathway to advanced non-invasive diagnostics in precision oncology? Mol Diagn Ther. 2021;25(4):389–408.
   PubMed Web of Science ®Google Scholar
• Kohabir K, Wolthuis R, Sistermans EA. Fragmentomic cfDNA patterns in noninvasive prenatal testing and beyond. J Biomed Transl Res. 2021;2021:10.
   Google Scholar
• Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385–389.
   PubMed Web of Science ®Google Scholar
• Mathios D, Johansen JS, Cristiano S, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12(1):5060.
   PubMed Web of Science ®Google Scholar
• Vessies DCL, Schuurbiers MMF, van der Noort V, et al. Combining variant detection and fragment length analysis improves detection of minimal residual disease in post-surgery circulating tumour DNA of stage II-IIIA NSCLC patients. Mol Oncol. 2022;2022:1.
   Google Scholar
• Yin R, Wang S, Li M, et al. Utilization of cell-free DNA fragmentomics in minimal residual disease detection for non-small cell lung cancer. J Clin Oncol. 2022;40(16_suppl):3038.
   Web of Science ®Google Scholar
• Choudhury Y, Pinweha P, Poh J, Lim JS, Tan M-H. Early detection of cancer using cell-free DNA (cfDNA) size analysis on a multiplexed amplicon-based next-generation sequencing (NGS) platform. J Clin Oncol. 2022;40(16_suppl):3041.
   Google Scholar
• Chen K, Shields MD, Chauhan PS, et al. Commercial ctDNA assays for minimal residual disease detection of solid tumors. Mol Diagn Ther. 2021;25(6):757–774.
   PubMed Web of Science ®Google Scholar
• Salazar MC, Rosen JE, Wang Z, et al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol. 2017;3(5):610–619.
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985.
   PubMed Web of Science ®Google Scholar
• Westeel V, Lebitasy MP, Mercier M, et al. Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC). Annals of Oncology. 2017;28(5):V452. doi:10.1093/annonc/mdx378.012.
   Google Scholar
• Westeel V, Barlesi F, Foucher P, et al. Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC). Ann Oncol. 2017;28:V452.
   Web of Science ®Google Scholar
• NCCN. NCCN guidelines. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 13, 2023.
   Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21.
   PubMed Web of Science ®Google Scholar
• Modh A, Rimner A, Williams E, et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014;90(5):1168–1176.
   PubMed Web of Science ®Google Scholar
• Kimura T, Matsuura K, Murakami Y, et al. CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? Int J Radiat Oncol Biol Phys. 2006;66(2):483–491.
   PubMed Web of Science ®Google Scholar
• Voroney JP, Hope A, Dahele MR, et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J Thorac Oncol. 2009;4(8):1035–1037.
   PubMed Web of Science ®Google Scholar
• Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–877.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552–3559.
   PubMed Web of Science ®Google Scholar
• Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, Phase 3 trial. Lancet. 2021;398(10308):1344–1357.
   PubMed Web of Science ®Google Scholar
• O’Brien MER, Paz-Ares L, Jha N, et al. EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. J Clin Oncol. 2022;40(16_suppl):8512.
   Web of Science ®Google Scholar
• Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–1723.
   PubMed Web of Science ®Google Scholar
• Zhou C, Srivastava W, Zou H, et al. 2O - IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Ann Oncol. 2021;32:S1373–S1391.
   Web of Science ®Google Scholar
• Solomon BJ, Ahn JS, Barlesi F, et al. ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(15_suppl):TPS8569–TPS8569.
   Web of Science ®Google Scholar
• Goldman JB, Wu B, Yang Y, et al. P01.01 LIBRETTO-432: a placebo-controlled phase 3 study of adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC. J Thorac Oncol. 2021;16(10):S975–976.
   Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl4):iv192–iv237.
   PubMed Web of Science ®Google Scholar
• Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra392.
   Web of Science ®Google Scholar
• Tie J, Wang Y, Cohen J, et al. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study. PLoS Med. 2021;18(5):e1003620.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;2022:1.
   Google Scholar
• Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432–437.
   PubMed Web of Science ®Google Scholar
• Trapani D, Franzoi MA, Burstein HJ, et al. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Ann Oncol. 2022;2022:1.
   Google Scholar
• Cherny NI, Dafni U, Bogaerts J, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28(10):2340–2366.
   PubMed Web of Science ®Google Scholar
• Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017;15(1):134.
   PubMed Web of Science ®Google Scholar
• Genomics Ci. C2i genomics. Available from: https://c2i-genomics.com/clinicians/. Accessed March 13, 2023.
   Google Scholar
• Tan AC, Saw SP, Lai GG, et al. Abstract 5114: ultra-sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (NSCLC). Cancer Res. 2022;82(12_Supplement):5114.
   Google Scholar
• Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586–5594.
   PubMed Web of Science ®Google Scholar